Fig. 3

Lmcd1 silencing results in reduced protein synthesis and decreased intrinsic force, without muscle atrophy. a Gastrocnemius mass normalized by mouse body weight 7 days after intramuscular delivery of a scrambled/control shRNA or a shLmcd1 (n = 6). b In vivo muscle protein synthesis by puromycin incorporation, and corresponding quantification (n = 6). c Isolated fiber diameter and representative microscopy image (× 200) in mice treated as in (a) (n = 10). Scale bar = 30 μm. d Force normalized for the cross-sectional area (specific force) for the different frequency tested (15–150 Hz) at 1-min interval in mice treated as in (a) (n = 10). e Myoplasmic free Ca²⁺ concentration for the different frequency tested (15–150 Hz) at 1-min interval in mice treated as in (a) (n = 10). f Mean value for specific force and myoplasmic free Ca²⁺ concentration for the different frequencies tested (15–150 Hz) at 1 min intervals in mice treated as in (a) (n = 10). g Percentage of force relative to the first contraction. Peak force was measured at 70 Hz tetani of 350 ms duration given at 2-s intervals for 50 contractions in mice treated as in (a) (n = 10). h Myoplasmic free Ca²⁺ concentrations at 150 Hz with caffeine treatment before and after fatigue protocol as in (g) (n = 10). Data is shown as mean ± SEM and *p < 0.05; **p < 0.01